Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Florian S. Wedl"'
Autor:
Franz Waibl, Monica L. Fernández-Quintero, Florian S. Wedl, Hubert Kettenberger, Guy Georges, Klaus R. Liedl
Publikováno v:
Frontiers in Molecular Biosciences, Vol 9 (2022)
While antibody-based therapeutics have grown to be one of the major classes of novel medicines, some antibody development candidates face significant challenges regarding expression levels, solubility, as well as stability and aggregation, under phys
Externí odkaz:
https://doaj.org/article/8b0bdc4c923f411f9bbae0b02b7643c8
Autor:
Monica L. Fernández-Quintero, Patrick K. Quoika, Florian S. Wedl, Clarissa A. Seidler, Katharina B. Kroell, Johannes R. Loeffler, Nancy D. Pomarici, Valentin J. Hoerschinger, Alexander Bujotzek, Guy Georges, Hubert Kettenberger, Klaus R. Liedl
Publikováno v:
Frontiers in Molecular Biosciences, Vol 9 (2022)
Externí odkaz:
https://doaj.org/article/863a1215e8194a08a42b208a8195a801
Autor:
Monica L. Fernández-Quintero, Patrick K. Quoika, Florian S. Wedl, Clarissa A. Seidler, Katharina B. Kroell, Johannes R. Loeffler, Nancy D. Pomarici, Valentin J. Hoerschinger, Alexander Bujotzek, Guy Georges, Hubert Kettenberger, Klaus R. Liedl
Publikováno v:
Frontiers in Molecular Biosciences, Vol 9 (2022)
As the current biotherapeutic market is dominated by antibodies, the design of different antibody formats, like bispecific antibodies and other new formats, represent a key component in advancing antibody therapy. When designing new formats, a target
Externí odkaz:
https://doaj.org/article/54e0f0f4d5ce4f6eb11bbfda2d108352
Autor:
Monica L. Fernández-Quintero, Patrick K. Quoika, Florian S. Wedl, Clarissa A. Seidler, Katharina B. Kroell, Johannes R. Loeffler, Nancy D. Pomarici, Valentin J. Hoerschinger, Alexander Bujotzek, Guy Georges, Hubert Kettenberger, Klaus R. Liedl
Publikováno v:
Frontiers in Molecular Biosciences, Vol 9 (2022)
As the current biotherapeutic market is dominated by antibodies, the design of different antibody formats, like bispecific antibodies and other new formats, represent a key component in advancing antibody therapy. When designing new formats, a target